Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 959 vs Eculizumab in PNH (DAHLIA)
NCT03818607Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2019
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of eculizumab-aeeb in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Amgen. Primary endpoints: Lactate Dehydrogenase Level at Week 27 and Time-adjusted Area Under the Effect Curve of LDH. Started Jan 2019; status: completed.
02
Drugs
eculizumab-aeeb
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03818607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818607.